http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008531501-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N43-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2006-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2008531501-A |
| titleOfInvention | Method for improving oral bioavailability of drugs and less toxic orotate composition |
| abstract | The present invention relates to methods for improving the oral bioavailability of pharmaceuticals, reducing the toxicity and side effects of chemotherapy, and improving the effectiveness of pharmaceuticals that are difficult to be absorbed by the gastrointestinal tract. In particular, the present invention relates to pharmaceuticals that are difficult to absorb, and to converting the pharmaceuticals to orotates. The present invention relates to a method for improving the treatment of a patient by oral administration of the pharmaceutical product. The drug orotate can be administered at low doses and can provide the effects obtained at higher doses. In addition, the lower dose reduces toxic effects. Furthermore, orotate has a higher clearance rate and reduces the likelihood of drug-induced liver damage. Therefore, the orotate formulation of a particularly useful pharmaceutical product allows rapid onset of drug efficacy and long-lasting effects at low doses, while allowing drug interactions and reduced side effects. [Selection] Figure 4 |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017203038-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015042270-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013503861-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016026213-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020105178-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016515619-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014513682-A |
| priorityDate | 2005-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 153.